Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.83 |
| ▸ | RAB9A | P51151 | 5/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526264 | 0.94 | NPC1 (0.83) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL11761142 | 0.92 | NPC1 (0.82) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL9416606 | 0.92 | NPC1 (0.82) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL1926263 | 0.91 | NPC1 (1.00) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL8432161 | 0.90 | NPC1 (0.69) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL5331526 | 0.88 | MMP13 (0.74) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL11900090 | 0.86 | HDAC6 (0.85) | RAB9AHPGDEPHX2NR1H4HDAC2 | |
| SCHEMBL25442568 | 0.86 | NPC1 (0.74) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL12215290 | 0.86 | NPC1 (0.74) | NPC1RAB9AHPGDALDH1A1CYP1A2 | |
| SCHEMBL5863585 | 0.86 | NPC1 (0.74) | NPC1RAB9AHPGDALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| CN-118005468-B | Method for synthesizing N-alkylated amide compound by catalyzing alcohols and nitriles with nitrogen-carbon material | 常州大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-118005468-A | Method for synthesizing N-alkylated amide compound by catalyzing alcohols and nitriles with nitrogen-carbon material | 常州大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-110818576-B | Secondary amine derivative synthesized by rare earth catalysis and preparation method thereof | 温州大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-110818576-A | Secondary amine derivative synthesized by rare earth catalysis and preparation method thereof | 温州大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-105016938-B | Method for preparing N-alkyl amide | 南京理工大学 | 2017-04-19 | — | — | CN | disclosed |
| US-9463451-B2 | Ligand, metal complex containing ligand, and reaction using metal complex containing ligand | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-10-11 | — | — | US | disclosed |
| CN-105820061-A | Method for synthesizing N-alkylamide | 南京理工大学 | 2016-08-03 | — | — | CN | disclosed |
| US-9334230-B2 | Process of forming an amide | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-10 | — | — | US | disclosed |
| US-20160107151-A1 | LIGAND, METAL COMPLEX CONTAINING LIGAND, AND REACTION USING METAL COMPLEX CONTAINING LIGAND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-04-21 | — | — | US | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-20070141630-A1 | IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY | GENENTECH, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070141630-A1 | IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY | GENENTECH, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| CN-1791412-A | Novel compounds and their use in therapy | SOLVAY PHARM GMBH (NL) | 2006-06-21 | — | — | CN | disclosed |
| US-6958243-B2 | Performing a one-pot organic reaction, which includes carbon monoxide (CO) as reactant and does not use of an external gas source, by contacting a non-catalyzing CO releasing compound such as a metal carbonyl with an energy source | BIOTAGE AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050221389-A1 | Organic reactions with CO generating materials | BIOTAGE AB (SE) | 2005-10-06 | — | — | US | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
| US-20020161266-A1 | Performing a one-pot organic reaction, which includes carbon monoxide (CO) as reactant and does not use of an external gas source, by contacting a non-catalyzing CO releasing compound such as a metal carbonyl with an energy source | BIOTAGE AB (SE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | NPC1 618/4885RAB9A 3568/4885HPGD 96/4885 |
| US-20160107151-A1 | LIGAND, METAL COMPLEX CONTAINING LIGAND, AND REACTION USING METAL COMPLEX CONTAINING LIGAND | HRH3, HRH2, HRH4 | NPC1 4631/4885RAB9A 461/4885HPGD 2575/4885 |
| US-20050221389-A1 | Organic reactions with CO generating materials | KIT, NOS1, NOS2 | NPC1 2348/4885RAB9A 2410/4885HPGD 531/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | NPC1 618/4885RAB9A 3568/4885HPGD 96/4885 |
| US-20020161266-A1 | Performing a one-pot organic reaction, which includes carbon monoxide (CO) as reactant and does not use of an external gas source, by contacting a non-catalyzing CO releasing compound such as a metal carbonyl with an energy source | KIT, CBR1, NOS1 | NPC1 2484/4885RAB9A 2457/4885HPGD 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.